Evidence demonstrating the oncogenic role of CXCR4 and a putative role as therapeutic target is present in Ewing sarcoma, osteosarcoma, rhabdomyosarcoma and synovial sarcoma. This evidence concerns the gene CXCR4 and synovial sarcoma.